More healthcare news
Are pharmacy benefit managers complicating the cost of your breast cancer care?
- 11/19/26

It is shameful that seriously ill patients must jump through hoops and risk financial ruin to access [testing and treatment] that is already protected by law.
If you’ve filled prescriptions using Express Scripts, OptumRx, or CVS Caremark, you have likely dealt with a pharmacy benefits manager (PBM).
PBMs are third-party companies that manage prescription drug plans for many health insurers, self-insured employer plans, and some Medicare Part D and Medicaid programs. Once your doctor writes a prescription, PBMs affect almost everything else down the line. They help decide which medications will be covered by your plan (the “formulary”) and which pharmacies you can use, process claims and appeals, and negotiate discounts with manufacturers. They often work with insurance companies or employers to make these decisions.
Emerging in the 1960s, PBMs were supposed to help streamline processes for patients and insurers. However, since the 1990s, patient advocates and legislators have voiced increasing concern about PBMs consolidating into fewer, larger companies, and integrating with insurers under one corporate umbrella, according to nonprofit health policy group KFF. Critics of PBMs argue that certain practices — including rebate arrangements and “spread pricing” — can create financial incentives for manufacturers to actually increase prices, while limiting transparency about how they operate.
As of 2025, about 80% of all U.S. prescription drug claims went through the top three PBMs. These three are subsidiaries of huge healthcare companies that may also own pharmacies: Express Scripts is owned by Cigna; CVS Caremark is owned by CVS Health, which also owns Aetna and — for now — the CVS retail pharmacy chain; and OptumRx is owned by UnitedHealth Group. Express Scripts is now the largest PBM, followed by CVS Caremark and Optum Rx. In November 2026, CVS Health announced it would split its retail pharmacy stores into another company, while keeping the Aetna and Caremark businesses together.
PBMs, insurers, or both can determine which medications need prior authorization and how often they need re-authorization. LBBC community members report that frequent re-authorizations can be time-consuming — and infuriating. In their experience, frontline customer service representatives at PBMs often do not understand specialized breast cancer medications or the urgency of avoiding any breaks in treatment.
The U.S. Oncology Network has testified to the Federal Trade Commission that “PBMs interfere with the doctor-patient relationship, drive up healthcare costs, and delay delivery of life-saving treatments.” Crucially for your finances, PBMs — often working with insurance companies or employer-sponsored health plans — may also determine whether any co-pay assistance you receive (for example, a manufacturer’s coupon) counts toward your deductible and annual maximum out-of-pocket obligation.
Erin Dalder-Alpher: Focusing on the good
When Erin Dalder-Alpher was first diagnosed with stage Ia invasive lobular breast cancer in 2020, she and her husband relied on Erin’s employer-sponsored health insurance. Information from biomarker testing enabled her to avoid chemotherapy, and she had a bilateral mastectomy and reconstruction, followed by five years in remission.
A routine scan in 2025 revealed evidence of cancer in Erin’s right hip. When a bone biopsy produced ambiguous results, her healthcare team ordered a liquid biopsy. Even though the results allowed Erin to skip traditional radiation and chemotherapy, her insurer classified the liquid biopsy as “out-of-network,” instantly fulfilling her $5,000 deductible. But after Erin’s deductible story appeared with others in a local news report, the company reversed course and covered the test, as mandated by law in her home state of Maryland.
Despite that reversal, Erin’s stage IV diagnosis drained the family’s entire $10,000 emergency savings, leaving them feeling financially precarious. Erin had enjoyed her job as a scientific meetings manager, but she could no longer handle the frequent travel and 14- to 16-hour days. She left work on disability and switched to health insurance through her husband’s employer, while waiting the required two years before she would qualify for Medicare.
Now, Erin takes an oral CDK4/6 inhibitor, abemaciclib (Verzenio) plus the aromatase inhibitor letrozole (Femara), and zoledronic acid (Zometa) infusions to protect her bones. She calls the results “nothing short of miraculous,” noting that her oncology team is “treating me like I have a chronic illness.”
Under Erin’s current insurance plan, she is required to get abemaciclib through CVS Specialty, and CVS Caremark is the PBM. The reported monthly medication cost is about $16,000 before insurance and assistance. The co-pay is over $5,000 monthly — impossible for her to pay. Erin’s sister helped her find a manufacturer’s co-pay coupon to ease that burden.
Even though Maryland law states that the manufacturer’s co-pay must be counted towards Erin’s out-of-pocket deductible, it does not. Her research revealed that their insurance comes from her husband’s union, which is based in California. Maryland’s state insurance protections do not apply to their plan. The law in California currently allows the use of “accumulators,” a type of program for cost management that PBMs are permitted, but not required, to follow. In some cases, a self-funded health plan would also be exempt from local insurance regulations.
Erin’s family now faces a dizzying kind of math. “This coming year, we’ll have coinsurance on top of deductibles. I need a PET scan every six months to check for progression. That’s 90% covered by insurance and it still costs me $550.” They have one maximum out-of-pocket limit annually per person, and a much higher one for the family.
“We’ll know more about 2027 changes in the next few months,” she says, adding, “What keeps me up at night is: What if I need more PET scans — how will I pay? And what happens when I get really sick? Breast cancer changes your life, changes your direction. I never thought I’d be here, but I’m just trying to focus on the good.”
What are co-pay accumulators and maximizers?
Around 2019, co-pay accumulators became an increasingly common feature in prescription drug coverage agreements. Accumulators allow the PBM or insurers to exclude the value of co-pay assistance from the patient’s annual deductible and maximum out-of-pocket costs, where permitted by law. For example, if you used a $25,000 manufacturer’s coupon to help pay your monthly co-pay, that $25,000 would not be credited to you. Once the assistance reaches its maximum, you would start at zero to pay down your full deductible.
Maximizers work a little differently but also benefit insurers. They allow insurance companies to collect as much manufacturer co-pay assistance as possible, often spreading it throughout the year. Like accumulators, this assistance may not count toward your deductible or maximum out of pocket costs. The key difference:
- Accumulator: focuses on not counting manufacturer assistance toward your deductible
- Maximizer: focuses on collecting as much manufacturer assistance as possible
According to one healthcare advocacy group, “These programs subject patients to annual cost-sharing obligations that often far exceed the amounts that are permitted by law and that are advertised in plan marketing materials.”
Many states have passed laws restricting the use of accumulators, but enforcement has been limited. Legislation to make all co-pays count for the benefit of patients has been introduced repeatedly in Congress, with no result. As of January 2026, co-pay accumulator bans were still pending in 14 states, including California and Pennsylvania.
If you’re uncertain whether your insurance plan uses as PBM, a co-pay accumulator, or a maximizer, call the customer service number on your pharmacy benefits card. Ask whether manufacturer co-pay assistance counts toward your deductible and maximum out-of-pocket costs. Your state department of insurance may also explain which laws apply to your plan.
- Use this interactive U.S. map from the Immune Deficiency Foundation to find out whether accumulators and maximizers are legal in your state.
- Find your state insurance department in this directory.
- Find more information from Triage Cancer about co-pay accumulator laws in your state.
Stay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
